This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
EMA and the Heads of Medicines Agencies (HMA), through the Executive Steering Gr...
CVMP opinions on veterinary medicinal productsThe Committee adopted by consensus...
The Clinical Trials Information System (CTIS) has been designated as a primary r...
EMA has issued recommendations for the influenza virus strains that vaccine manu...
EMA is exploring improvements to the development and evaluation of biosimilar me...
For the first time, all the 27 countries of the European Union (EU27) together w...
Five new medicines recommended for approvalEMA’s human medicines committee (CHMP...
EMA’s human medicines committee (CHMP) has issued the first Qualification Opinio...
EMA and the Heads of Medicines Agencies (HMA) have published their joint EU medi...
Election of new Management Board ChairAt its March meeting, EMA’s Management Bor...
At its monthly meeting, EMA’s safety committee (PRAC) carried out its broad rang...
EMA and the Heads of Medicines Agencies (HMA) are warning the public about the d...
At its 13 March meeting, EMA’s Management Bord elected Rui Santos Ivo as chair o...
A new clinical trial map is now accessible from the public website of the Clinic...
Four new medicines recommended for approvalEMA’s human medicines committee (CHMP...
EMA’s environmental management system has been certified with the Eco-Management...
CVMP opinions on veterinary medicinal productsThe Committee adopted by consensus...
CVMP opinions on veterinary medicinal productsThe Committee adopted by consensus...
At its monthly meeting, EMA’s safety committee (PRAC) carried out its broad rang...
EMA, in close collaboration with the European Commission, has established a stan...
EMA has published an overview of its key recommendations of 2024 regarding the a...
CVMP opinions on veterinary medicinal productsThe Committee adopted by consensus...
Medicines containing semaglutide: PRAC investigating risk of rare eye conditionP...
In 2024, EMA recommended 114 medicines for marketing authorisation. Of these, 46...